Strem and Codexis Sign Enzyme Distribution Agreement
News Feb 20, 2013
These enzymes enable efficient conversion of ketones to chiral alcohols or amines.
The screening kits contain enzymes evolved with proprietary CodeEvolver® directed evolution technology. The resulting enzymes are designed to work at industrial process conditions while reducing cost and waste. They will be available through Strem’s overnight delivery service so that researchers are able to quickly screen a small number of diverse biocatalysts to pick the best solution.
“We are pleased to announce this partnership with Strem, a company very well established in the distribution of catalysts to a wide customer base,” said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. “Based on Strem’s proven network, we are looking forward to giving more customers the opportunity to use industrial enzymes at R&D scale.”
“Strem is pleased to be working with a proven market leader in the field of Biocatalysis,” said Ephraim Honig, Chief Operating Officer at Strem. “The addition of these screening kits broadens the range of synthesis tools we offer our customers and acknowledges the increasingly important role this technology plays in drug discovery and development.”
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE